UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The time of equipoise on the use of biological DMARDs in for inflammatory arthritis during pregnancy is finally over: a reappraisal of evidence to optimise pregnancy management

Giles, Ian; Thorne, Iona; Schmidt, Nanna Surlemont; Reid, Claire; Crossley, Amy; Panca, Monica; Freemantle, Nick; ... Clowse, Megan EB; + view all (2024) The time of equipoise on the use of biological DMARDs in for inflammatory arthritis during pregnancy is finally over: a reappraisal of evidence to optimise pregnancy management. Lancet Rheumatology 10.1016/S2665-9913(24)00097-3. (In press).

[thumbnail of Article] Text (Article)
Giles_Equipoise in IA pregnancy Final Nov 23 clean version.pdf
Access restricted to UCL open access staff until 12 December 2024.

Download (243kB)
[thumbnail of Table] Text (Table)
Giles_Tables for Equipoise in IA final Oct 2023.pdf
Access restricted to UCL open access staff until 12 December 2024.

Download (206kB)
[thumbnail of Figure 1] Text (Figure 1)
Equipoise Fig 1. v3.pptx - Accepted Version
Access restricted to UCL open access staff until 12 December 2024.

Download (280kB)
[thumbnail of Figure 2] Text (Figure 2)
Equipoise Fig 2. v3.pptx - Accepted Version
Access restricted to UCL open access staff until 12 December 2024.

Download (281kB)

Abstract

Active inflammatory arthritis in pregnancy is associated with an increased risk of adverse pregnancy outcomes. Treatment of active inflammation and maintenance of low disease activity with medication reduces these risks. Therapeutic decisions on disease-modifying antirheumatic drugs (DMARDs) in pregnancy are complicated by safety concerns, which have led to inappropriate withdrawal of treatment and consequential harm to mother and fetus. Studies of inflammatory arthritis in pregnancy have consistently shown minimal safety concerns with the use of biological DMARDs and an increased risk of disease flare with discontinuation of biological DMARDs. It is our opinion that during pregnancy, the benefits of disease control with biological DMARDs, when required in addition to conventional synthetic DMARDs, outweigh the risks. In this Series paper, we review the reasons for reconsideration of equipoise and propose an agenda for future research to optimise the use of biological DMARDs in inflammatory arthritis during pregnancy.

Type: Article
Title: The time of equipoise on the use of biological DMARDs in for inflammatory arthritis during pregnancy is finally over: a reappraisal of evidence to optimise pregnancy management
Location: England
DOI: 10.1016/S2665-9913(24)00097-3
Publisher version: https://doi.org/10.1016/S2665-9913(24)00097-3
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10194338
Downloads since deposit
6Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item